Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases in the United States and other markets. The company’s lead product candidate is IMCIVREE (setmelanotide), which is being studied and used across a range of rare genetic and hypothalamic obesity-related conditions, including POMC, LEPR and PCSK1 deficiency obesity, Bardet-Biedl syndrome, Alstrom syndrome, Prader-Willi syndrome, and hypothalamic obesity. Rhythm is also advancing bivamelagon, an oral MC4R agonist in phase 2 testing for MC4R pathway diseases, and RM-718, a next-generation MC4R peptide agonist in phase 1 development for hypothalamic obesity. The company was founded in 2008, adopted its current name in 2015, and is headquartered in Boston, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RYTM
|
$96.47
|
8.1% Upside
|
Fair
|
$140.53
|
57.4% Upside
|
Bargain
|
Fair
|
0.0%
|
59.7x
|
25.6x
|
6.146 B
|
6.04 B
|
1.7%
|
81.4%
|
11.9
|
50.6%
|
